Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...
FiercePharma22h
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
BioSpace21h
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Morphine Market to Reach USD 32.81 Billion by 2032 Amid Rising Demand for Pain Management and Cough Suppressant Applications | SNS Insider
Rising Prevalence of Chronic Pain Conditions and the Geriatric Population Drive Morphine Market GrowthPune, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The SNS Insider report indicates that, “The global ...
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...